PFS by MRD status among patients who achieved ≥CR. PFS by MRD status (10⁻⁵) among all patients who achieved ≥CR (A) and patients in the pooled daratumumab-combination groups vs the pooled control groups (B) from POLLUX, CASTOR, ALCYONE, and MAIA. Shown are Kaplan-Meier estimates of PFS based on MRD status (MRD negative or positive) as measured using the threshold of 1 tumor cell per 10⁵ white cells among patients in the ITT population who achieved ≥CR according to IMWG criteria. In CASTOR and ALCYONE, standard of care was given for a fixed number of cycles, and daratumumab was given until disease progression. In POLLUX and MAIA, patients who received standard of care or daratumumab-based regimens received study treatment until disease progression or unacceptable toxicity.